A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
…, AJ Verkleij, GAMS van Dongen… - … journal of cancer, 2011 - Wiley Online Library
The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for
antibody‐based therapy. At present, several anti‐EGFR monoclonal antibodies have been …
antibody‐based therapy. At present, several anti‐EGFR monoclonal antibodies have been …
[HTML][HTML] Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)
…, F Manca, DJ Vugts, B Windhorst, GAMS van Dongen… - PloS one, 2014 - journals.plos.org
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment
with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that …
with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that …
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies
…, GB Snow, GAMS Van Dongen - Journal of nuclear …, 2003 - Soc Nuclear Med
The use of immuno-PET, the combination of PET with monoclonal antibodies (mAbs), is an
attractive option to improve tumor detection and mAb quantification. The long-lived positron …
attractive option to improve tumor detection and mAb quantification. The long-lived positron …
The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
A Van Rhenen, GAMS Van Dongen… - Blood, The Journal …, 2007 - ashpublications.org
In CD34 + acute myeloid leukemia (AML), the malignant stem cells reside in the CD38 −
compartment. We have shown before that the frequency of such CD34 + CD38 − cells at …
compartment. We have shown before that the frequency of such CD34 + CD38 − cells at …
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
…, M Budde, P Jurek, GE Kiefer, GAMS Van Dongen - Nature protocols, 2010 - nature.com
The positron emitter zirconium-89 ( 89 Zr) has very attractive properties for positron
emission tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. …
emission tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. …
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft
…, AH Brouwers, GA Van Dongen… - Journal of Nuclear …, 2007 - Soc Nuclear Med
Vascular endothelial growth factor (VEGF), released by tumor cells, is an important growth
factor in tumor angiogenesis. The humanized monoclonal antibody bevacizumab blocks VEGF…
factor in tumor angiogenesis. The humanized monoclonal antibody bevacizumab blocks VEGF…
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging
…, LR Perk, GAMS van Dongen… - Journal of nuclear …, 2009 - Soc Nuclear Med
The anti–human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is
administered to patients with HER2/neu-overexpressing breast cancer. Whole-body …
administered to patients with HER2/neu-overexpressing breast cancer. Whole-body …
Immuno-PET: a navigator in monoclonal antibody development and applications
GAMS Van Dongen, GWM Visser… - The …, 2007 - academic.oup.com
Learning Objectives After completing this course, the reader will be able to: Discuss the
technical advances that have led to recent rapid developments in monoclonal antibody imaging …
technical advances that have led to recent rapid developments in monoclonal antibody imaging …
Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
…, HJ de Haard, CR Leemans, GAMS van Dongen - Molecular cancer …, 2008 - AACR
The ∼15-kDa variable domains of camelid heavy-chain-only antibodies (called Nanobodies)
can easily be formatted as multivalent or multispecific single-chain proteins. Because of …
can easily be formatted as multivalent or multispecific single-chain proteins. Because of …
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
…, A Staab, CR Leemans, GAMS Van Dongen - Clinical Cancer …, 2006 - AACR
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary
efficacy of bivatuzumab mertansine. Bivatuzumab is a humanized monoclonal antibody directed …
efficacy of bivatuzumab mertansine. Bivatuzumab is a humanized monoclonal antibody directed …